Neutrophil function during chemotherapy for Hodgkin's disease

Area of Science:

• Immunology
• Oncology
• Hematology

Background:

• Hodgkin's disease (HD) is a malignancy of the lymphatic system.
• Chemotherapy is a primary treatment for advanced HD.
• Neutrophil dysfunction can increase infection susceptibility in cancer patients.

Purpose of the Study:

• To assess neutrophil function during chemotherapy for advanced Hodgkin's disease.
• To investigate the impact of chemotherapy on neutrophil migration, phagocytosis, and antimicrobial activity.
• To differentiate between cell-associated and plasma-related neutrophil defects.

Main Methods:

• Simultaneous measurement of neutrophil migration, phagocytosis, candidacidal, and bactericidal activity.
• Comparison of neutrophil function in patients with advanced HD (untreated, on chemotherapy, in remission) and healthy controls.
• Assessment of functional defects in relation to chemotherapy cycles and plasma factors.

Main Results:

• Neutrophil migration and phagocytosis were generally normal, with occasional plasma-corrected depressions.
• Neutrophil candidacidal and bactericidal activity were frequently depressed during chemotherapy, worsening in later cycles.
• Killing activity defects were often correctable by normal plasma, indicating a plasma-related component.

Conclusions:

• Most patients with advanced Hodgkin's disease have normal neutrophil function.
• A subset of patients on chemotherapy exhibit significant neutrophil killing defects, partly plasma-dependent.
• Defective neutrophil function may contribute to increased infection risk during Hodgkin's disease chemotherapy.